Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Boston Medical Center
- Study ID
- NCT00898235
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- clonality analysis — GENETICanalyze clonality
- polymerase chain reaction — GENETICanalyze polymerase chain reaction
- protein analysis — GENETICanalyze protein
- biologic sample preservation procedure — OTHERpreserve biologic samples
- laboratory biomarker analysis — OTHERanalyze laboratory biomarkers
- fluorescence spectroscopy — PROCEDUREperform fluorescence spectroscopy on specimens
- quality-of-life assessment — PROCEDUREassess quality of life at each follow-up for life
Study Details
RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases
Key Dates
- Start date
- Jan 31, 2000
- Status verified
- Nov 2025
- Primary completion
- Dec 31, 2040
- Completion
- Dec 31, 2040
Study Design
- Enrollment
- 10,000 participants (estimated)
Primary Outcome Measure
Establish a repository to promote biochemical research [ Time Frame: life of study ]
Central Contacts
- Vaishali Sanchorawala, MD617-638-8261
- Annie Jose, BS617 638 8213
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Boston University Cancer Research Center | Boston | Massachusetts | 02118 | Clinical Trials Office - Boston University Cancer Research Cen 617-638-8265 |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.PHASE1 · Recruiting · Newave Pharmaceutical Inc · Chicago, Illinois
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)PHASE1/PHASE2 · Recruiting · Sumitomo Pharma America, Inc. · Newport Beach, California